Jennifer Lachey - Jan 5, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jan 5, 2022
Transactions value $
-$158,205
Form type
4
Date filed
1/7/2022, 03:35 PM
Previous filing
Dec 15, 2021
Next filing
Jan 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $795 +2.65K +3.09% $0.30* 88.4K Jan 5, 2022 Direct
transaction KROS Common Stock Sale -$159K -2.65K -3% $60.00 85.7K Jan 5, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -2.65K -2.78% $0.00 92.6K Jan 5, 2022 Common Stock 2.65K $0.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.